Open AccessFirst Allogeneic CAR T‐Cell Therapy Impresses in Relapsed/Refractory Lymphoma
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0570
Subject(s) - medicine , refractory (planetary science) , regimen , follicular lymphoma , lymphoma , clinical trial , oncology , salvage therapy , dermatology , chemotherapy , physics , astrobiology
In the phase I ALPHA trial, the first allogeneic “off‐the‐shelf” CAR T‐cell therapy regimen showed clinical benefits in patients with relapsed/refractory large B‐cell or follicular lymphoma.